2. Cardiovascular Disease

Cardiovascular Disease

Cardiovascular Disease

Related Products

PDF 32.36 MB

Cardiovascular diseases (CVDs) are the leading causes of death and disability worldwide. CVDs include diseases of the heart, vascular diseases of the brain and diseases of blood vessels. Caused by atherosclerosis, coronary heart disease and cerebrovascular disease are the most common forms of CVDs. Other less common forms of CVDs include rheumatic heart disease and congenital heart disease. A large percentage of CVDs is preventable through the reduction of behavioral risk factors such as tobacco use, physical inactivity and unhealthy diet. Dietary sodium reduction can alleviate the long-term risk of cardiovascular disease events. Statin therapy is an effective intervention in both the primary and secondary preventions of CVDs in those who are at high risk.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-115381
    Lipoxin A5 110657-98-2 98%
    Lipoxin A5 is an eicosapentaenoic acid derived from pig white blood cells. Lipoxin A5 slowly contracted the guinea pig lung parenchymal strips with a contractile force similar to that of LXA4 and LXB4.2, but LXA5 did not have the vasodilating effect on the aortic smooth muscle shown by LXA4 and LXB4.2.
    Lipoxin A5
  • HY-115474
    Cardionogen-2 578755-52-9 98%
    Cardionogen-2 is a biphasic modulator of cardiogenesis, either promoting or inhibiting heart formation depending on the stage of treatment. Cardionogen-2 inhibits Wnt/β-catenin-dependent transcription in murine embryonic stem (ES) cells and zebrafish embryos.
    Cardionogen-2
  • HY-115862
    Benzo[c][1,8]naphthyridin-6(5H)-one 53439-81-9 98%
    Benzo[c][1,8]naphthyridin-6(5H)-one exhibits low micromolar affinity to human adenosine receptor (AR) A1 and hA2A, with Ki of 4.6 and 4.8 μM. Benzo[c][1,8]naphthyridin-6(5H)-one is inhibitor for poly ADP-ribose polymerase-1 (PARP-1) and aurora kinase A, with IC50 of 0.311 and 5.5 μM.
    Benzo[c][1,8]naphthyridin-6(5H)-one
  • HY-116072
    Antiarrhythmic agent-2 105919-73-1 98%
    Antiarrhythmic agent-2 is a nonspecific Ca2+ inward current blocker that inhibits ionic currents in sensory neuron membranes. Antiarrhythmic agent-2 can be used in the study of cardiovascular diseases, such as arrhythmias.
    Antiarrhythmic agent-2
  • HY-116150
    Xymedon 14716-32-6 98%
    Xymedon is a pyrimidine derivative with anti-atherosclerotic effects. Xymedon reducts plasma cholesterol levels and cholesterol esterification in blood vascular cells.
    Xymedon
  • HY-116233
    ROCK-IN-13 1219727-16-8 98%
    ROCK-IN-13 is a ROCK2 inhibitor with an IC50 of 8 nM against human ROCK2. ROCK-IN-13 has the potential for use in the research of diseases such as multiple sclerosis, glaucoma, and cardiovascular diseases.
    ROCK-IN-13
  • HY-116262
    SCH 51866 167298-74-0 98%
    SCH 51866 is a potent, selective and orally active inhibitor of PDE1 (IC50=70 nM) and PDE5 (IC50=60 nM). SCH 51866 inhibits collagen-induced aggregation of human washed platelets (IC50=10 μM), prevents neointimal formation in balloon catheter-injured carotid arteries of spontaneously hypertensive rats (SHR), and reduces blood pressure in SHR. SCH 51866 can be used in the study of hypertension.
    SCH 51866
  • HY-116281
    ICI D1542 147332-48-7 98%
    ICI D1542 is a selective and potent inhibitor of thromboxane A2 (TXA2) synthase and the thromboxane A2 receptor (TP-receptor). ICI D1542 is effective at preventing thrombus formation by redirection of arachidonic acid metabolism.
    ICI D1542
  • HY-116307
    2-Thio-UTP 35763-29-2 98%
    2-Thio-UTP is a selective P2Y2 inhibitor with an EC50 value of 50 nM. 2-Thio-UTP reduces pro-fibrotic gene expression and protein α-smooth muscle actin. 2-Thio-UTP has the potential for the research of calcific aortic valve stenosis (CAVS) .
    2-Thio-UTP
  • HY-116680
    LY53857 60634-51-7 98%
    LY53857 is a potent antagonist of vasoconstriction and serotonin-mediated 5-HT2 receptors. LY53857 did not reduce mean arterial blood pressure in spontaneously hypertensive rats (SHR) at doses that blocked the depressor response to serotonin and blocked central serotonin receptors. In addition, LY53857 was able to enhance neurotransmitter release in rat vas deferens and guinea pig ileal nerves.
    LY53857
  • HY-116913
    Moxicoumone 17692-56-7 98%
    Moxicoumone is an anticoagulant.
    Moxicoumone
  • HY-116957
    Bunitrolol hydrochloride 29876-08-2 98%
    Bunitrolol hydrochloride is an orally active β-adrenergic blocker that has a high affinity for β-adrenergic receptors. Bunitrolol hydrochloride exerts significant β-receptor antagonist activity and has weak α1-blocking activity. Bunitrolol hydrochloride is mainly used in the study of cardiovascular diseases such as hypertension and angina pectoris, and is also used in placental transport research.
    Bunitrolol hydrochloride
  • HY-117055
    Ro 18-3981 103295-92-7 98%
    Ro 18-3981 is a dihydropyridine that inhibits cardiac Ca2+ channels. Ro 18-3981 shows higher inhibitory activity when the cell membrane is in a depolarized state (Vh=-20 mV: IC50=2.3 nM; Vh=-50 mV: IC50=100 nM).
    Ro 18-3981
  • HY-117123
    Convulxin 37206-04-5 98%
    Convulxin is a toxin found in a tropical rattlesnake. Convulxin stimulates platelet aggregation, and clusters GPVI to trigger Src family kinase activation, Fc receptor γ chain phosphorylation, and p72SYK signaling. Convulxin interacts with Dectin-2 to induce IL-10 production, activates monocytes to generate ROS and NLRP3 inflammasome-mediated IL-1β secretion, and induces mitochondrial ROS. Convulxin causes transient arterial blood pressure changes in dogs. Convulxin can be used for research related to coagulation.
    Convulxin
  • HY-117131
    ZINC17167211 592539-21-4 98%
    ZINC17167211 is a potent PPAR-α agonist (EC50=0.16 nM) that can be used in the study of diabetes, hyperlipidemia, and inflammatory diseases.
    ZINC17167211
  • HY-117443
    IWP-051 1354041-91-0 98%
    IWP-051 is an agonist for soluble guanylate cyclase with an EC50 of 290 nM. IWP-051 stimulates the generation of cGMP, and exhibits the synergistic effect with NO. IWP-051 exhibits good pharmacokinetic characteristics in rats.
    IWP-051
  • HY-117464
    CM-352 1664361-37-8 98%
    CM-352 (compound 5) is an inhibitor of matrix metalloproteinases (MMPs) (MMP-3: IC50=15 nM; MMP-10: IC50=12 nM). CM-352 has significant antifibrinolytic activity (EC50=0.7 nM) and can significantly prolong blood coagulation time. CM-352 can be used in anti-bleeding research.
    CM-352
  • HY-117561
    DuP 714 130982-43-3 98%
    DuP 714 is an oral active thrombin inhibitor with the IC50 values of 150 nM aganist thrombin-induced aggregation in washed human platelets. DuP 714 can be used for study of arterial thrombosi.
    DuP 714
  • HY-117607
    Alatrioprilat 135038-59-4 98%
    Alatrioprilat is an orally active inhibitor of angiotensin-converting enzyme (ACE) (IC50=19.6 nM; Ki=9.8 nM) and enkephailnase (IC50=6.1 nM; Ki=5.1 nM). Alatrioprilat plays a key role in the metabolism of hormonal peptides through the degradation of nitric oxide and atrial natriuretic factor (ANF). Alatrioprilat can be used in the study of cardiovascular diseases.
    Alatrioprilat
  • HY-117627
    L 158338 133240-38-7 98%
    L 158338 is an angiotensin II receptor antagonist. L 158338 alleviates acidosis and increases coronary blood flow during the ischemic period and increases coronary blood flow during the reperfusion period. L 158338 can be used to study myocardial injury during ischemia and reperfusion.
    L 158338
Cat. No. Product Name / Synonyms Application Reactivity